香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：1513） 截至2024年6月30日止六個月的未經審計中期業績公告 麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「本公司」，連同其附屬公 司統稱為「本集團」）董事會（「董事會」）謹此宣佈本集團截至2024年6月30日止六個月的未 經審計中期業績。本業績公告列載本公司2024年中期報告全文，並符合《香港聯合交易所 有限公司證券上市規則》中有關中期業績初步公告附載的資料之要求。 本業績公告的中英文版本可在本公司網站(www.livzon.com.cn)和香港交易及結算所有限公 司（「香港交易所」）網站(www.hkexnews.hk)查閱。 2024年中期報告將於適當時候於香港交易所網站(w ...

Financial Performance - In 2023, Livzon Pharmaceutical Group achieved a revenue of RMB 12,430.04 million, a year-on-year decrease of 1.58%[8] - The net profit attributable to shareholders was RMB 1,953.65 million, reflecting a year-on-year growth of 2.32%[8] - The company reported a total operating revenue of RMB 12,430.04 million, reflecting a decrease of 1.58% compared to the previous year[15] - The net profit attributable to shareholders was RMB 1,953.65 million, with a decrease of 2.32% year-on-year[15] - The company reported a significant decline of 79.33% in revenue from traditional Chinese medicine products, totaling RMB 84.43 million[19] - The company achieved a 17.18% increase in cash flow from operating activities, amounting to RMB 2,382.67 million[16] - The company reported a total cash flow from operating activities of RMB 1.04 billion in Q4 2023, showing a positive trend in cash generation[39] - The company’s net profit from core business, excluding non-recurring items, was RMB 1,881.35 million, a slight increase of 0.05% year-on-year[48] - The company reported a significant increase of 6,218.19% in current non-current liabilities, primarily due to the reclassification of long-term borrowings[100] Dividend Distribution - The company plans to distribute a cash dividend of RMB 13.50 per 10 shares, pending approval at the annual general meeting[8] - The dividend distribution is based on the total share capital as of the record date, excluding repurchased but not canceled shares[20] - The expected payment dates for the cash dividends are July 8, 2024, for A-share shareholders and August 5, 2024, for H-share shareholders[20] Research and Development - The company has made significant progress in its R&D innovation system, focusing on differentiated product pipelines in areas such as oncology and reproductive health[9] - The company plans to focus on enhancing R&D efficiency in innovative drugs and complex formulations, particularly in gastrointestinal, mental health, reproductive assistance, and oncology fields[13] - The company has initiated multiple clinical trials, including a Phase III trial for recombinant human IL-17A/F monoclonal antibody injection and completed enrollment for semaglutide injection for type 2 diabetes[10] - The company is focusing on R&D in high-barrier complex formulations and innovative drugs, particularly in reproductive health and oncology[41] - The company is actively pursuing non-equity investments, with a focus on securities investments valued at RMB 198,586,942.57[128] - The company is committed to increasing its R&D investment to improve innovation capabilities and adapt to industry policy changes[182] - The company emphasizes the importance of addressing unmet clinical needs and will continue to invest in innovative research and development of high-value innovative drugs and complex formulations[186] Product Development and Approvals - In 2023, 40 innovative drugs were approved for listing in China, maintaining a stable number of new drug approvals[7] - New products approved in 2023 include Triptorelin Acetate Microspheres and a new indication for Apremilast, enhancing the company's competitive position in various therapeutic areas[9] - The company received emergency use approval for a bivalent COVID-19 vaccine in December 2023, improving accessibility for patients[9] - The company has successfully launched several new products, including tocilizumab injection and new indications for injectable esomeprazole sodium, which are expected to enhance the product pipeline in their respective therapeutic areas[81] - The company is advancing multiple clinical research projects, including treatments for prostate cancer and gastrointestinal diseases, which are expected to enrich its product pipeline[88] Market Strategy and Expansion - The company aims to accelerate the internationalization of its products to ensure sustainable long-term development[9] - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by 2025[27] - The company has introduced innovative drugs in the gastrointestinal and cardiovascular fields, enhancing its international collaboration and licensing efforts[11] - The company is focusing on expanding its product offerings in the mental health sector with the development of Paliperidone injection for schizophrenia, currently in BE testing[85] - The company is exploring international markets and partnerships for innovative drug development to support its globalization strategy[186] Sustainability and ESG - The company’s MSCI ESG rating reached the highest level of AAA, making it the first Chinese pharmaceutical company to achieve this rating[12] - The company aims to achieve carbon neutrality by 2055, emphasizing its commitment to sustainable development and environmental responsibility[14] - The company is committed to strict compliance with environmental regulations, which may increase operational costs but is essential for sustainable practices[189] Financial Management and Investments - The company has invested 150 million RMB in new technology development, focusing on advanced manufacturing processes[27] - The company has completed 167 registration projects for raw materials and intermediates in 103 overseas countries/regions, with 27 international certification certificates obtained[56] - The company has reported a significant asset impairment of ¥310,038,083.02, accounting for -13.01% of total profit, primarily due to inventory write-downs[92] - The company has capital commitments totaling RMB 709.93 million as of December 31, 2023, significantly up from RMB 406.79 million at the end of 2022[116] - The company has made significant equity investments totaling RMB 702,000,000, with a projected loss of RMB -11,178,981.98 for the current period[126] Investor Relations - The company engaged in multiple investor communications throughout 2023, including discussions with institutions like 博裕资本 and IronBirch Capital regarding operational conditions and future development directions[191][192] - The company maintained transparency by not providing any written materials during these discussions, ensuring that all information shared was accurate and factual[191][192] - The company’s investor relations activities were consistently documented and made available on the 巨潮 website for public access[191][192] Operational Efficiency - The company is committed to enhancing its internal operations management and improving supply chain efficiency through smart manufacturing and automation[176] - The company has established a comprehensive quality management system, ensuring the safety and stability of its products[65] - The company is enhancing its quality management system and production processes, leading to improved operational capabilities and cost control[52]

Financial Performance - The company's operating revenue for Q1 2024 was CNY 3,242,814,513.73, a decrease of 4.99% compared to CNY 3,413,055,191.98 in the same period last year[6] - Net profit attributable to shareholders for Q1 2024 was CNY 607,823,809.46, representing an increase of 4.45% from CNY 581,909,331.89 year-on-year[6] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.65, up 4.84% from CNY 0.62 in the same quarter last year[6] - The company reported a gross profit margin of approximately 64.7%, compared to 63.1% in the previous period, indicating an improvement in profitability[38] - The total comprehensive income for the current period is RMB 693,127,170.79, an increase from RMB 547,848,808.47 in the previous period[39] Cash Flow - The net cash flow from operating activities surged by 208.30% to CNY 924,248,920.31, compared to CNY 299,784,593.85 in the previous year[6] - Cash flow from operating activities increased by 208.30% to RMB 924.25 million, attributed to reduced procurement and expense outflows[22] - Operating cash flow for the current period is RMB 924,248,920.31, a significant increase from RMB 299,784,593.85 in the previous period, reflecting a growth of approximately 208.5%[41] - Total cash inflow from operating activities is RMB 3,508,763,815.99, compared to RMB 3,446,124,787.42 in the prior period, indicating a slight increase of about 1.8%[41] - The net increase in cash and cash equivalents for the current period is -RMB 188,391,565.87, compared to an increase of RMB 527,826,015.13 in the previous period[43] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 25,189,695,757.11, reflecting a slight increase of 0.58% from CNY 25,044,827,127.75 at the end of the previous year[8] - The total liabilities decreased to RMB 9,750,195,000.46 from RMB 10,278,124,131.71, reflecting a reduction of approximately 5.12%[37] - The company's total equity increased to RMB 15,439,500,756.65 from RMB 14,766,702,996.04, representing a growth of about 4.54%[37] - The company's cash and cash equivalents stood at RMB 11,143,148,609.60, down from RMB 11,325,723,855.76 at the beginning of the year[35] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 43,751, with 43,538 being A-share shareholders[25] - The largest shareholder, Hong Kong Central Clearing Limited, holds 33.41% of shares, totaling 309,547,589 shares[25] - The company has initiated a share buyback program, resulting in treasury shares amounting to CNY 128,431,667.85[17] - The company repurchased a total of 2,152,600 A-shares, accounting for 0.23% of the total share capital, with a total expenditure of RMB 73,436,534.00[30] - The company also repurchased 2,476,300 H-shares, representing 0.27% of the total share capital, with a total expenditure of HKD 60,363,260.00[31] Investment and Income - Investment income decreased by 58.41% to RMB 15.72 million, primarily due to last year's dividend income[22] - The company reported a 238.80% increase in minority shareholders' profit to RMB 108.26 million, driven by improved performance of non-wholly owned subsidiaries[22] - Other comprehensive income improved by 65.23%, primarily due to changes in the fair value of other equity instruments and foreign exchange fluctuations[22] Research and Development - Research and development expenses for the current period were RMB 238,173,559.46, down 23.5% from RMB 311,408,248.52 in the previous period[38] Other Financial Metrics - Non-recurring gains and losses for the period totaled CNY 17,522,920.17, primarily driven by government subsidies and asset disposals[13] - Other receivables increased by 43.55% to CNY 45,948,492.93, mainly due to an increase in export tax refunds[17] - The company reported a significant increase of 203.07% in other current assets, totaling CNY 156,230,044.47, attributed to new cash management operations[17] - The company's short-term borrowings decreased to RMB 1,360,009,625.00 from RMB 1,860,009,625.00, a reduction of 27%[37] - The deferred income tax liabilities decreased to RMB 202,497,603.77 from RMB 209,812,292.82, a decline of about 3.5%[37] Audit Status - The company has not undergone an audit for the first quarter report[45]

Financial Performance - For the year 2023, the company achieved a revenue of RMB 12,430.04 million, a year-on-year decrease of 1.58%[16] - The net profit attributable to shareholders for 2023 was RMB 1,953.65 million, representing a year-on-year increase of 2.32%[16] - Excluding non-recurring gains and losses, the net profit from core business for 2023 was RMB 1,881.35 million, a slight increase of 0.05% year-on-year[16] - The company reported total operating revenue of RMB 12,430.04 million, representing a year-on-year increase of 2.94%[28] - The net profit attributable to shareholders was RMB 1,744.89 million, reflecting a growth of 14.04% compared to the previous year[29] - The company reported a net profit of RMB 581,909,331.89 thousand in the first quarter of 2023[65] - The company reported a total operating cost of RMB 4,465,473,361.10, a slight increase of 0.09% from RMB 4,461,283,076.09 in 2022[118] - The income tax expense for the year was RMB 485.07 million, an increase of 29.36% year-on-year, primarily due to the company's operating results[129] - The company has made adjustments to previous years' financial data due to changes in accounting policies[58] Dividend and Shareholder Returns - The board proposed a cash dividend of RMB 13.50 per 10 shares (before tax) for the 2023 fiscal year, pending approval at the annual general meeting[17] - The company plans to distribute a cash dividend of RMB 13.50 per 10 shares to all shareholders, pending approval at the 2023 annual general meeting[37] - The dividend distribution is expected to occur on July 8, 2024, for A-share shareholders and August 5, 2024, for H-share shareholders[37] Research and Development - In 2023, the company focused on R&D innovation, particularly in the fields of digestive, mental health, reproductive assistance, and oncology, enhancing its differentiated product pipeline[18] - The company has established a robust R&D innovation system, optimizing management structures across clinical operations and drug safety, leading to accelerated realization of innovative research outcomes[18] - The company aims to enhance R&D efficiency and strengthen its leading position in innovative drugs and complex formulations, focusing on areas such as digestive, mental health, reproductive assistance, and oncology[24] - The company has initiated multiple clinical trials, including a Phase III trial for recombinant human IL-17A/F monoclonal antibody injection and completed enrollment for semaglutide injection for type 2 diabetes[20] - The company has made significant progress in R&D, with the approval of the injection of Triptorelin Acetate microspheres for prostate cancer and the completion of Phase III clinical trials for endometriosis[78] - The company is advancing several R&D projects, including a long-acting implant for prostate cancer and a micro-injection for endometriosis, all in preclinical research stages[137] Market Expansion and Product Development - The company accelerated the internationalization of its products, contributing to a comprehensive enhancement of its long-term sustainable development capabilities[14] - The company introduced innovative drugs in the gastrointestinal and cardiovascular fields, strengthening its international collaboration and licensing efforts[21] - The company has analyzed potential risk factors and response strategies for future development in the management discussion and analysis section of the report[37] - Livzon plans to expand its market presence in Southeast Asia, targeting a 30% increase in sales from this region by 2025[45] - The company is actively pursuing international collaboration and innovation business models to enhance its global market presence[69] - The company is focusing on high-barrier complex formulations and innovative drugs, strengthening its integrated raw material and formulation capabilities[98] Environmental and Social Responsibility - The company achieved an MSCI ESG rating of AAA, becoming the first Chinese pharmaceutical company to receive this highest rating[23] - The company plans to achieve carbon neutrality by 2055 and is committed to increasing environmental protection investments[26] Financial Position and Assets - The total assets as of December 31, 2023, were RMB 25,044,827.13 thousand, reflecting a 0.71% increase from the previous year[59] - The total liabilities increased by 3.49% to RMB 10,278,124.13 thousand as of December 31, 2023[59] - The return on equity attributable to shareholders was 13.91%, an increase of 0.15 percentage points compared to the previous year[59] - The company's asset-liability ratio increased from 39.94% in 2022 to 41.04% in 2023[157] - The total outstanding debt as of December 31, 2023, is RMB 5,014.84 million, an increase from RMB 4,604.43 million as of December 31, 2022, representing an increase of 8.9%[171] Risk Management and Compliance - The company has implemented long-term equity incentive plans to motivate employees and align their growth with the company's development[23] - The company continues to address corruption issues in the pharmaceutical industry through a comprehensive governance approach initiated by the National Health Commission[3] - Forward-looking statements in the report are subject to risks and uncertainties, and actual results may differ significantly from these statements[37] Investment and Financing Activities - The company has made significant equity investments, including RMB 600 million in Wuhan Kangli Health Investment, acquiring a 60% stake, and RMB 102 million in Guangdong Lijian Animal Health, acquiring a 51% stake[183] - The total investment amount for the year reached RMB 729.64 million, a significant increase of 1,724.08% compared to RMB 40.00 million in the previous year[182] - The company has capital commitments totaling RMB 709.93 million, which includes commitments for long-term asset construction and R&D expenditures[168] Product Pipeline and Approvals - The company has successfully launched several new products, including tocilizumab injection and new indications for injectable esomeprazole sodium, enhancing its product pipeline in various therapeutic areas[131] - The company has received emergency use authorization for the recombinant novel coronavirus fusion protein vaccine, which is expected to enrich its vaccine product pipeline[133] - The injectable progesterone solution for women undergoing assisted reproductive technology has been submitted for approval, aiming to expand the company's offerings in the reproductive health sector[133] - The injectable phosphoric acid tedizolid for acute bacterial skin and skin structure infections has been submitted for market approval, which will enhance the company's infection control product pipeline[133]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 麗 珠醫 藥集 團股 份有 限公 司 LIVZON PHARMACEUTICAL GROUP INC.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：1513） 2023年第三季度報告 麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「公司」或「本公司」，連同其 附屬公司，統稱「本集團」）根據香港聯合交易所有限公司證券上市規則第13.09條和第13.10B 條以及香港法例第571章證券及期貨條例第XIVA部內幕消息條文刊發本公告。 本公司及董事會全體成員保證信息披露的內容真實、準確、完整，沒有虛假記載、誤導性陳 述或重大遺漏。 重要內容提示： 1. 本公司董事會、監事會及董事、監事、高級管理人員保證公司2023年第三季度報告（「本 季度報告」）的真實、準確、完整，不存在虛假記載、誤導性陳述或重大遺漏，並承擔 ...

Financial Performance - Livzon Pharmaceutical reported a revenue of RMB 6,689.92 million for the first half of 2023, representing a 6.15% increase compared to the same period in 2022[15]. - The net profit attributable to shareholders was RMB 1,227.31 million, reflecting a decrease of 13.96% year-over-year[15]. - The basic earnings per share increased by 11.93% to RMB 1.22 compared to RMB 1.09 in the previous year[16]. - Livzon Pharmaceutical's cash flow from operating activities was RMB 1,423.37 million, showing a 6.15% increase from the previous year[15]. - The company achieved operating revenue of RMB 6,689.92 million, a year-on-year increase of 6.15% compared to RMB 6,302.57 million in the same period last year[43]. - Net profit attributable to shareholders reached RMB 1,134.57 million, reflecting an 11.50% increase from RMB 1,017.55 million in the previous year[43]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 1,093.71 million, up 4.52% from RMB 1,046.42 million in the same period last year[43]. - The company reported a total income tax expense of RMB 249.30 million, which is a 21.57% increase year-on-year, primarily due to higher taxable income[76]. Revenue Breakdown - Revenue from chemical preparations reached RMB 3,480.29 million, accounting for 52.02% of total revenue[16]. - The revenue from biological products increased by 14.26% to RMB 953.85 million[16]. - The revenue from traditional Chinese medicine preparations reached RMB 953.85 million, a year-on-year increase of 94.42%, accounting for 14.26% of the total revenue[57]. - The revenue from diagnostic reagents and equipment was RMB 297.99 million, a year-on-year decrease of 13.88%, representing 4.45% of the total revenue[58]. - The revenue from APIs and intermediates was RMB 1,781.67 million, a year-on-year increase of 3.03%, accounting for 26.63% of the total revenue[54]. - The revenue from chemical agents was RMB 3,480.29 million, a year-on-year decrease of 2.42%, accounting for 52.02% of the total revenue[45]. - The revenue from biological products was RMB 113.41 million, a year-on-year increase of 5.93%, accounting for 1.70% of the total revenue[51]. Strategic Initiatives - The company is focusing on new product development and market expansion strategies to enhance growth prospects[18]. - Livzon plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2024[30]. - The company is investing RMB 200 million in R&D for new drug development, focusing on innovative therapies for chronic diseases[30]. - Livzon is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[30]. - The company is actively pursuing international cooperation and licensing for its innovative products and pipelines, with ongoing discussions with multiple international partners[60]. - The company has achieved a strategic partnership with leading global pharmaceutical companies, enhancing its market position[54]. Research and Development - The company has made significant progress in the development of new drugs, including the approval of the injection of leuprolide acetate microspheres for prostate cancer[46]. - The company has registered 20 products in 11 overseas countries/regions as of the end of the reporting period[49]. - The company has completed 135 international registration projects for APIs and intermediates in 63 overseas countries/regions[55]. - The company has nine ongoing research projects in traditional Chinese medicine, with the SXSHL gel completing preclinical studies and the TGDX granules finishing clinical trials[57]. - The company has 7 ongoing research projects for complex formulations, with 1 approved for market and 1 completing Phase III clinical trials[79]. - A total of 27 key projects are under research, with 3 approved for market and 4 in the production application stage[80]. - In the biopharmaceutical sector, there are 8 ongoing projects, with 2 approved for market and 1 approved for emergency use[81]. Market Expansion and Sales - User data indicates a growth in customer base by 25%, with over 5 million active users engaging with the company's products[30]. - The company expects a revenue guidance of RMB 2.5 billion for the full year 2023, reflecting a growth rate of 18%[30]. - The company plans to strengthen its marketing efforts in traditional Chinese medicine, focusing on the sales of specific products like the Qishi Fuzheng injection in oncology and expanding into pediatric and geriatric medicine[182]. - The company aims to improve its supply chain efficiency and strengthen quality management to prevent major quality safety incidents[177]. - The company will continue to focus on the research, production, and sales of pharmaceutical products, including various formulations and active pharmaceutical ingredients[42]. Financial Position and Liabilities - The total assets increased by 3.46% to RMB 25,726.13 million from RMB 24,864.83 million at the beginning of the period[42]. - Total liabilities rose by 15.59% to RMB 11,476.30 million from RMB 9,928.57 million at the beginning of the period[42]. - The asset-liability ratio rose from 39.93% to 44.61% as of June 30, 2023, indicating a higher level of debt relative to assets[94]. - The company's long-term borrowings rose by 32.81% to RMB 2,622,263,438.94, primarily due to new bank loans[92]. - The group’s total borrowings amounted to RMB 4,232.26 million as of June 30, 2023, up from RMB 3,596.68 million as of December 31, 2022, representing 16.45% of total assets[105]. Investment and Capital Expenditure - The company has invested RMB 54,850.66 million in the Sichuan Guangda relocation and expansion project, with government subsidies totaling RMB 17,443.17 million received[120]. - The company plans to invest a total of RMB 20,820.90 million in the new product development and industrial upgrading project, with expected annual investments over the next five years[145]. - The company has committed to using the raised funds for specific projects, including the development of innovative products and technology upgrades, aligning with its strategic goals[141]. - The company has reported a significant increase in investment amounting to RMB 727,085,150.00 for the current period, compared to RMB 30,000,065.77 in the previous period, reflecting a change of 2,323.61%[123]. - The company has allocated RMB 51,685.32 million for replenishing working capital and repaying bank loans, achieving 100% of the planned investment[154]. Risk Management and Compliance - The company has implemented a foreign exchange risk management system to mitigate the impact of currency fluctuations on its business[112]. - The company is actively monitoring industry policy changes and will strengthen its compliance and operational capabilities in response to evolving regulations[185]. - The company has established risk management measures to mitigate market, operational, and legal risks associated with derivative investments[136]. - The company aims to enhance its operational efficiency through improved risk management practices in derivative trading[136]. Sustainability and Environmental Initiatives - The company aims to achieve carbon neutrality by 2055, enhancing its commitment to green and low-carbon operations[195]. - The company has established GAP production bases for key traditional Chinese medicine raw materials to mitigate supply risks[194]. - The company aims to establish a green ecological planting base for key medicinal materials to support its core product research and development[182].

Financial Performance - The company's operating revenue for the six months ended June 30, 2023, was RMB 6,689.92 million, representing a 6.15% increase compared to the same period last year[15]. - The net profit attributable to shareholders for the same period was RMB 1,227.31 million, reflecting a decrease of 13.96% year-on-year[15]. - The basic earnings per share increased by 11.93% to RMB 1.22 compared to the previous period[16]. - The company reported a net cash flow from operating activities of RMB 1,046.42 million, which is a 4.52% increase from the previous year[15]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2023, representing a 15% year-over-year growth[30]. - The company achieved operating revenue of RMB 6,689.92 million in the first half of 2023, a year-on-year increase of 6.15% compared to RMB 6,302.57 million in the same period last year[43]. - The net profit attributable to shareholders reached RMB 1,134.57 million, reflecting a year-on-year growth of 11.50% from RMB 1,017.55 million[43]. Revenue Breakdown - Revenue from chemical preparations reached RMB 3,480.29 million, accounting for 52.02% of total revenue, with a growth of 26.63%[16]. - The revenue from biological products was RMB 1,781.67 million, showing a growth of 14.26% year-on-year[16]. - The revenue from the raw materials and intermediates segment reached RMB 1,781.67 million, a year-on-year increase of 3.03%, accounting for 26.63% of the total revenue[54]. - The revenue from the Chinese medicine preparation segment reported revenue of RMB 953.85 million, a significant year-on-year growth of 94.42%, representing 14.26% of the total revenue[57]. - The revenue from diagnostic reagents and equipment decreased to RMB 297.99 million, a decline of 13.88%, making up 4.45% of the total revenue[58]. Market Expansion and Strategy - The company is focusing on expanding its market presence and enhancing its product offerings[18]. - Market expansion plans include entering two new international markets by Q4 2023, aiming for a 5% market share in each[30]. - The company actively expanded its international market presence, focusing on product registration in countries such as Pakistan, Indonesia, and Uzbekistan, with 20 product specifications registered in 11 overseas countries/regions[49]. - The company is considering strategic acquisitions to enhance its product portfolio, with a target of completing at least one acquisition by the end of the fiscal year[30]. Research and Development - The company is investing heavily in R&D, with a budget increase of 25% for new drug development initiatives[30]. - The company is enhancing its R&D capabilities and international collaboration to strengthen its competitive edge in various therapeutic areas[63]. - The company is focusing on innovative drugs and high-barrier complex formulations, leveraging its unique advantages in raw materials and formulations integration[64]. - The company is advancing key projects in the field of biological products, including the approval of the recombinant human chorionic gonadotropin injection for overseas registration in Tajikistan and ongoing submissions in other countries[51]. Operational Efficiency - The gross margin improved to 45%, up from 42% in the previous year, reflecting better cost management[30]. - The company has implemented new technologies in production, resulting in a 30% increase in efficiency[30]. - The company is enhancing its production and quality management systems to improve product delivery capabilities and reduce operational costs through lean production initiatives[48]. - The company has implemented measures to improve operational efficiency and safety awareness among employees through training programs[61]. Financial Position and Liabilities - Total assets at the end of the period were RMB 25,726,127,198.95, representing a 3.46% increase from RMB 24,864,825,366.23 at the beginning of the period[36]. - Total liabilities increased by 15.59%, reaching RMB 11,476,301,953.22 compared to RMB 9,928,573,774.51 at the beginning of the period[36]. - The company's asset-liability ratio rose from 39.93% as of December 31, 2022, to 44.61% as of June 30, 2023[94]. - Long-term borrowings increased by 32.81% to RMB 2,622,263,438.94, attributed to new bank loans[93]. Investment and Capital Expenditure - The company has invested RMB 54,850.66 million in the Sichuan Guangda relocation and expansion project, with government subsidies totaling RMB 17,443.17 million received[120]. - The company made significant investments totaling RMB 727,085,150.00 during the reporting period, a 2,323.61% increase compared to the previous period's investment of RMB 30,000,065.77[123]. - The company plans to invest a total of RMB 20,820.90 million in the new product development and industrial upgrading project, with an expected completion date by December 31, 2020[145]. - The company has committed to using the raised funds for various projects, including the development of innovative products and technology platforms, in line with its strategic goals[141]. Compliance and Risk Management - The company has established risk control measures to mitigate market, operational, and legal risks associated with derivatives trading[136]. - The company emphasizes the importance of regulatory compliance and environmental management, increasing investments in environmental protection equipment[195]. - The company is actively monitoring industry policy changes and will strengthen its compliance and operational systems in response to evolving regulations[186]. Future Outlook - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 10% to 12%[30]. - The company plans to enhance its R&D efficiency and strengthen its innovative drug and complex formulation platforms in the second half of 2023[176]. - The company aims to deepen its market presence in key disease areas such as autoimmune diseases and respiratory infections through targeted sales management[183].

Financial Performance - In 2022, Livzon Pharmaceutical Group achieved a revenue of RMB 12,629.58 million, representing a year-on-year growth of 4.69%[8] - The net profit attributable to shareholders for 2022 was RMB 1,909.39 million, an increase of 7.53% compared to the previous year[8] - Excluding non-recurring gains and losses, the net profit attributable to shareholders from core operations was RMB 1,880.46 million, reflecting a growth of 15.57% year-on-year[8] - The company reported a total revenue of RMB 12,629.58 million for the year, representing a 4.69% increase compared to the previous year[16] - The net profit attributable to shareholders was RMB 1,909.39 million, reflecting a growth of 7.53% year-on-year[16] - The company achieved a 15.57% increase in cash flow from operating activities, amounting to RMB 2,772.67 million[16] - The basic earnings per share for 2022 was RMB 2.04, a 7.37% increase from RMB 1.90 in 2021[42] - The total amount of public welfare donations made by the company during the reporting period was approximately RMB 9.98 million[12] Business Development and Strategy - Livzon is focusing on innovative drug development in areas such as digestive, mental health, reproductive assistance, and oncology, with a differentiated product pipeline covering the entire R&D cycle[11] - The company aims to strengthen its competitive advantage through digital transformation and improved operational management[7] - Livzon is actively pursuing business development opportunities, including potential mergers and acquisitions to enhance its product portfolio and market presence[31] - The company has expanded its market channels and established an internet digital marketing platform to increase product penetration in the OTC retail market[12] - The company is committed to enhancing its R&D pipeline, particularly in high-barrier complex formulations and innovative drugs, to meet evolving market demands[49] - The company is focusing on enhancing its product competitiveness through digital transformation and improving operational efficiency[57] Research and Development - Livzon has established a Clinical Research Management Center to optimize the management structure of its medical, clinical operations, and registration teams[11] - The company completed the Phase III clinical trial for the Semaglutide injection and submitted supplementary materials for the prostate cancer indication of Triptorelin microspheres[12] - The company has 86 ongoing R&D projects as of the end of 2022, with 1 project in the clinical evaluation stage[106] - The company has made significant progress in the research and development of complex formulations and new drugs in oncology, reproductive health, and autoimmune diseases[61] - The company is focusing on the development of new traditional Chinese medicine projects, with eight new drug research projects currently underway[72] Market Expansion - Livzon's market expansion efforts have led to a 20% increase in user data, with a growing customer base in both domestic and international markets[31] - The company is actively expanding its international business, particularly in markets such as Pakistan, Indonesia, and Uzbekistan[60] - The company has successfully registered 5 chemical preparation products in overseas markets and submitted 6 new registrations as of December 31, 2022[63] - The company is advancing the conditional listing application for its recombinant COVID-19 vaccine, which has been included in the national immunization program and is now used in over 20 provinces[64] Corporate Governance and Social Responsibility - The board proposed a cash dividend of RMB 16.00 per 10 shares for the 2022 fiscal year, pending approval at the annual general meeting[10] - The company is committed to social responsibility by providing precise assistance to chronic and rare disease patients, contributing to health initiatives in rural areas[15] - The company has established a foreign exchange risk management system to mitigate exposure from non-RMB transactions[147] Financial Position and Assets - Total assets as of December 31, 2022, reached RMB 24,864.83 million, an increase of 11.14% from RMB 22,371.92 million at the end of 2021[42] - The company reported a total of 935,552,687 shares outstanding as of the last trading day before disclosure[44] - The company's total assets increased from RMB 22,366,000,000.00 at the end of 2021 to RMB 24,900,000,000.00 at the end of 2022, reflecting a growth of approximately 11.3%[114] - Cash and cash equivalents rose to RMB 10,411,348,410.09, accounting for 41.87% of total assets, up from 40.88% in the previous year[114] Investment and Financial Management - The company has capital commitments of approximately RMB 406.79 million as of December 31, 2022, down from RMB 886.35 million at the end of 2021[142] - The investment amount for the year was RMB 40,000,152.05, representing a significant decrease of 95.49% compared to RMB 886,650,000.00 in the previous year[154] - The company received government subsidies totaling RMB 13,843.17 million for the Sichuan Guangda relocation and expansion project[151] - The financial performance indicates a need for improved management of investment risks, as evidenced by the reported losses[158] Risk Management - The report includes an analysis of potential risks and response strategies for future development[19] - Forward-looking statements in the report are subject to risks and uncertainties, and actual results may differ significantly from these statements[19] - The company emphasizes the importance of not relying on or using such information improperly, as it may lead to investment risks[19]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：1513） 2023年第一季度報告 麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「本公司」或「公司」，連同其附 屬公司，統稱「本集團」）根據香港聯合交易所有限公司證券上市規則第13.09條和第13.10B條以 及香港法例第571章證券及期貨條例第XIVA部內幕消息條文刊發本公告。 本公司及本公司董事會（「董事會」）全體成員保證信息披露的內容真實、準確、完整，沒有虛假 記載、誤導性陳述或重大遺漏。 重要內容提示： 1. 本公司董事會、監事會及董事、監事、高級管理人員保證公司2023年第一季度報告（「本 ...

[0 -> 28] 大家好欢迎参加力珠集团2022年业绩交流会目前所有参会者均处于静音状态现在开始Follow me的声明声明播报完毕后主持人可直接开始发言谢谢本次电话会议仅服务于新业证券客户会议音频及文字记录的内容版权为新业证券所有内容必须经新业证券审核后方可留存 [29 -> 51] 未经允许和授权转载转发此次会议内容均属侵权新义证券将保留追究其法律责任的权利电话会议所有参会人员不得泄露内幕信息以及未公开重要信息涉及外部嘉宾发言的新义证券不保障其发言内容的准确性与完整性 [51 -> 77] 深夜证券不承担外部嘉宾发言内容所引起的任何损失及责任不承担因转载转发引起的任何损失及责任市场有风险投资需谨慎提醒投资者注意投资风险审慎参考会议内容各位投资人上午好欢迎来到力柱集团2022年业绩交流会 [77 -> 105] 我們今天非常榮幸的邀請到公司管理層為我們線上解讀公司2022年的經營情況今天出席的公司領導有公司執行董事、總裁唐陽剛先生副董裁、財務負責人副董裁、董事會秘書楊亮先生研究院院長、化學藥首席科學家與務求公司總經理許堅先生我是興業證券的醫藥分析師黃漢陽 [105 -> 134] 那今天和我一同在线主持的 ...